Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.792290
Keywords
opioid receptor; cancer; metastasis; TLR4; OGFr; opioid antagonist
Categories
Ask authors/readers for more resources
Opioids are commonly used in cancer patients for pain management during tumor excision and to alleviate cancer-related pain. However, the effects of opioids on tumor growth and metastasis, as well as their impact on disease outcomes, are still under debate in literature. It is clear that opioids have direct and indirect effects on solid tumor biology, the anticancer immune response, inflammation, angiogenesis, and the tumor-promoting effects of pain.
Opioids are administered to cancer patients in the period surrounding tumour excision, and in the management of cancer-associated pain. The effects of opioids on tumour growth and metastasis, and their consequences on disease outcome, continue to be the object of polarised, discrepant literature. It is becoming clear that opioids contribute a range of direct and indirect effects to the biology of solid tumours, to the anticancer immune response, inflammation, angiogenesis and importantly, to the tumour-promoting effects of pain. A common misconception in the literature is that the effect of opioid agonists equates the effect of the mu-opioid receptor, the major target of the analgesic effect of this class of drugs. We review the evidence on opioid receptor expression in cancer, opioid receptor polymorphisms and cancer outcome, the effect of opioid antagonists, especially the peripheral antagonist methylnaltrexone, and lastly, the evidence available of a role for opioids through non-opioid receptor mediated actions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available